Intraperitoneal administration of butyrate prevents the severity of acetic acid colitis in rats

作     者：Joshua J.MALAGO Catherine L.SANGU 

作者机构：Department of PathologyFaculty of Veterinary MedicineSokoine University of Agriculture c/o Walter Oseko 

出 版 物：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 (浙江大学学报（英文版）B辑（生物医学与生物技术）)

年 卷 期：2015年第16卷第3期

页      面：224-234页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Butyrate Oral administration Intraperitoneal administration Intrarectal administration Acetic acid,Ulcerative colitis 

摘      要：Intrarectal infusion of butyrate improves colorectal disorders including ulcerative colitis （UC）. However, it is not established whether systemically administered butyrate benefits such patients. The current study aimed at ex- ploring and comparing the potential of intraperitoneally, intrarectally, and orally administered butyrate against acetic acid （AA）-induced UC in rats. Intrarectal administration of 2 ml of 50% AA was done after or without prior treatment of rats for 7 consecutive days with 100 mg/kg sodium butyrate （SB） intraperitoneally, intrarectally, or orally. Rats were sacrificed after 48 h of hA-treatment. Subsequently, colon sections were processed routinely for histopathological examination. We clinically observed diarrhea, loose stools, and hemoccult-positive stools, and histologically, epithelial loss and ulceration, crypt damage, goblet cell depletion, hemorrhage, and mucosal infiltration of inflammatory cells. The changes were significantly reduced by intraperitoneal, intrarectal, or oral butyrate, with intraperitoneal butyrate exhibiting the highest potency. It is concluded that intraperitoneal administration of butyrate abrogates the lesions of hA-induced UC and its potency surpasses that of intrarectal or oral butyrate.